Clinical trialNCT00335270CompletedPhase 4Interventional

A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination

SponsorDuke UniversityEnrollment100HIV

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the antiretroviral efficacy, safety, and tolerability of fos-amprenavir boosted with either of two doses of ritonavir (RTV) when administered in combination with ABC/3TC (abacavir/lamivudine, Epzicom®) FDC (fixed dose combination) in a once-daily regimen over 96 weeks in ART-naïve, HIV-infected adults

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Charles Hicks, MD
Duke University
Principal Investigator
clinicaltrials.gov ↗
David A Wohl, MD
University of North Carolina, Chapel Hill
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Jason Flamm, MD
Medicine 4
Principal Investigator
clinicaltrials.gov ↗
Jeffrey Lennox, MD
Emory University
Principal Investigator
clinicaltrials.gov ↗
Jeffrey P Nadler, MD
Hillsborough County Health Department
Principal Investigator
clinicaltrials.gov ↗
Jeffrey Stephens, MD
Mercer University School of Medicine
Principal Investigator
clinicaltrials.gov ↗
John H. Schrank, MD
Greenville Hospital System
Principal Investigator
clinicaltrials.gov ↗
Louis Sloan, MD
North Texas Infectious Disease Consultants
Principal Investigator
clinicaltrials.gov ↗
Rafael E Campo, MD
University of Miami
Principal Investigator
clinicaltrials.gov ↗
Rodger MacArthur, MD
Wayne State University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Miami School of Medicine
Miami, Florida, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Abacavir →Fos-amprenavir calcium, ritonavir

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2006
Primary completion: 31 Dec 2007
Completion: 31 Dec 2007
Last update posted: 14 May 2013
Registered enrollment: 100
Registry id: NCT00335270

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.